Feasibility trial of 3-phase adaptive dose painting by numbers for head and neck cancer: 3 years clinical results

被引：0
|
作者：
Berwouts, D. [1 ]
Duprez, F. [2 ]
Boterberg, T. [2 ]
De Gersem, W. [2 ]
Olteanu, A. M. L. [2 ]
Vercauteren, T. [2 ]
De Neve, W. [2 ]
机构：
[1] Univ Hosp Ghent, Radiat Oncol Nucl Med, Ghent, Belgium
[2] Univ Hosp Ghent, Radiat Oncol, Ghent, Belgium
来源：
RADIOTHERAPY AND ONCOLOGY | 2015年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1149
引用
收藏
页码：S624 / S625
页数：2
相关论文
共 50 条
  • [21] Comparative dosimetry of three-phase adaptive and non-adaptive dose-painting IMRT for head-and-neck cancer
    Olteanu, Luiza A. M.
    Berwouts, Dieter
    Madani, Indira
    De Gersem, Werner
    Vercauteren, Tom
    Duprez, Frederic
    De Neve, Wilfried
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 (03) : 348 - 353
  • [22] OPRAH: Phase 3 trial of optimum radiation dose for palliation in head and neck carcinoma
    Mallick, Supriya
    Dagar, Abhilash
    Ghosh, Adrija
    Hazarika, Sangeeta
    Raj, Jaswin
    Sharma, Aman
    Kumar, Akash
    Sharma, Jyoti
    Panda, Smriti
    Sharma, Dayanand
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1200 - S1201
  • [23] Repeatability of hypoxia dose painting by numbers based on EF5-PET in head and neck cancer
    Wright, Pauliina
    Arnesen, Marius Rothe
    Lonne, Per-Ivar
    Suilamo, Sami
    Silvoniemi, Antti
    Dale, Einar
    Minn, Heikki
    Malinen, Eirik
    ACTA ONCOLOGICA, 2021, 60 (11) : 1386 - 1391
  • [24] Clinical outcomes after re-irradiation with dose painting of head and neck cancer
    Dale, E.
    Evensen, M. E.
    Amdal, C. D.
    Furre, T.
    Moan, J. M.
    Londalen, A. M.
    Heggebo, L. C.
    Malinen, E.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S944 - S945
  • [25] Pravastatin reverses fibrosis in head and neck cancer patients: phase II clinical trial results
    Bourgier, C.
    Rivera, S.
    Vozenin, M. C.
    Boisselier, P.
    Azria, D.
    Lassau, N.
    Taourel, P.
    Bourhis, J.
    Deutsch, E.
    Auperin, A.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S250 - S250
  • [26] Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
    Colevas, A. D.
    Bahleda, R.
    Braiteh, F.
    Balmanoukian, A.
    Brana, I.
    Chau, N. G.
    Sarkar, I.
    Molinero, L.
    Grossman, W.
    Kabbinavar, F.
    Fasso, M.
    O'Hear, C.
    Powderly, J.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2247 - 2253
  • [27] Transparency in reporting of phase 3 cancer clinical trial results
    Patel, Roshal R.
    Verma, Vivek
    Fuller, Clifton D.
    McCaw, Zachary R.
    Ludmir, Ethan B.
    ACTA ONCOLOGICA, 2021, 60 (02) : 191 - 194
  • [28] Adaptive and robust FDG-PET-based dose painting by numbers (DPBN) in head and neck tumors: a methodological approach
    Differding, S.
    Sterpin, E.
    Lee, J. A.
    Gregoire, V.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S314 - S315
  • [29] Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer
    Rasmussen, Jacob H.
    Hakansson, Katrin
    Vogelius, Ivan R.
    Aznar, Marianne C.
    Fischer, Barbara M.
    Friborg, Jeppe
    Loft, Annika
    Kristensen, Claus A.
    Bentzen, Soren M.
    Specht, Lena
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 (01) : 76 - 80
  • [30] Robust maximization of tumor control probability for radicality constrained radiotherapy dose painting by numbers of head and neck cancer
    Gronlund, Eric
    Almhagen, Erik
    Johansson, Silvia
    Traneus, Erik
    Ahnesjo, Anders
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2019, 12 : 56 - 62
12345